

# John L Reagan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9516291/publications.pdf>

Version: 2024-02-01

66  
papers

736  
citations

516561

16  
h-index

580701

25  
g-index

67  
all docs

67  
docs citations

67  
times ranked

1497  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. <i>Blood</i> , 2022, 139, 1147-1159.	0.6	17
2	Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study. <i>Oncologist</i> , 2022, 27, 532-e542.	1.9	3
3	Antifungal prophylaxis during 7 + 3 induction chemotherapy for acute myeloid leukemia is associated with improved survival, in a setting with low incidence of invasive mold infections. <i>Supportive Care in Cancer</i> , 2021, 29, 707-712.	1.0	5
4	Antibiotic use during cytarabine consolidation in acute myeloid leukemia. <i>Annals of Hematology</i> , 2021, 100, 79-84.	0.8	3
5	Outcomes of lenalidomide- or bortezomib-based regimens in older patients with plasma cell myeloma. <i>American Journal of Hematology</i> , 2021, 96, 14-22.	2.0	4
6	Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethylators for acute myeloid leukemia. <i>Supportive Care in Cancer</i> , 2021, 29, 5323-5327.	1.0	14
7	3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-9.	0.6	5
8	Trials and Tribulations in the Frontline Treatment of Older Adults with Acute Myeloid Leukemia. <i>Hemato</i> , 2021, 2, 515-544.	0.2	0
9	Factors Associated with Seroconversion after COVID-19 Vaccination in Patients with Hematologic Malignancies. <i>Blood</i> , 2021, 138, 3511-3511.	0.6	2
10	Longitudinal Analysis of Hydroxyurea and Fetal Hemoglobin in Adult Patients with Sickle Cell Anemia. <i>Blood</i> , 2021, 138, 2054-2054.	0.6	0
11	Whole Genome Sequencing Identifies a Recurrent Mutation in Complement Factor I (CFI) in Primary Myelofibrosis (PMF). <i>Blood</i> , 2021, 138, 1472-1472.	0.6	2
12	Thrombosis in COVID-19: A Narrative Review of Current Literature and Inpatient Management. <i>Rhode Island Medical Journal (2013)</i> , 2021, 104, 14-19.	0.2	2
13	Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 354-361.	2.0	19
14	Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia. <i>Thrombosis Research</i> , 2020, 196, 375-378.	0.8	37
15	Adjuvant chemotherapy administration and survival outcomes of lymphoma survivors with common solid tumors: a population-based study. <i>Leukemia and Lymphoma</i> , 2020, 61, 3360-3368.	0.6	0
16	Asciminib in Relapsed Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2020, 382, 1378-1379.	13.9	3
17	Preliminary findings regarding the use of direct oral anticoagulants in cerebral venous thrombosis. <i>Clinical Neurology and Neurosurgery</i> , 2020, 198, 106204.	0.6	13
18	Inflammation-related gene expression profiles of salivary extracellular vesicles in patients with head trauma. <i>Neural Regeneration Research</i> , 2020, 15, 676.	1.6	17

#	ARTICLE	IF	CITATIONS
19	Vincristine Sulfate Liposome Injection (VSLI) with Bendamustine and Rituximab As First-Line Therapy for Indolent B-Cell Lymphomas: A Phase 1 Study. <i>Blood</i> , 2020, 136, 15-16.	0.6	1
20	Enforcing the "4T": An In-Line Calculator for HIT Antibody Ordering in the Electronic Medical Record. <i>Rhode Island Medical Journal</i> (2013), 2020, 103, 78-83.	0.2	0
21	Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base. <i>Leukemia and Lymphoma</i> , 2019, 60, 3426-3433.	0.6	8
22	Use of bone-modifying agents and clinical outcomes in older adults with multiple myeloma. <i>Cancer Medicine</i> , 2019, 8, 6945-6954.	1.3	5
23	Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 593-597.	0.2	10
24	Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy. <i>British Journal of Haematology</i> , 2019, 186, e31-e35.	1.2	17
25	Potential biomarkers to detect traumatic brain injury by the profiling of salivary extracellular vesicles. <i>Journal of Cellular Physiology</i> , 2019, 234, 14377-14388.	2.0	41
26	Bortezomib plus <sc>EPOCH</sc> is effective as frontline treatment in patients with plasmablastic lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 679-682.	1.2	55
27	Comparative Effectiveness of Lenalidomide, Bortezomib, and Their Combinations As First-Line Treatment of Older Patients with Myeloma. <i>Blood</i> , 2019, 134, 3155-3155.	0.6	1
28	Evaluating the Incidence of Cardiovascular and Thrombotic Events in Secondary Polycythemia. <i>Blood</i> , 2019, 134, 3511-3511.	0.6	4
29	BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 4460-4460.	0.6	1
30	Overexpression of Tpl2 is linked to imatinib resistance and activation of <sc>MEK</sc> and <sc>ERK</sc> and <sc>NF</sc> pathways in a model of chronic myeloid leukemia. <i>Molecular Oncology</i> , 2018, 12, 630-647.	2.1	35
31	Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2018, 181, 495-504.	1.2	21
32	Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 204-209.	0.2	6
33	Mechanisms of Hypercalcemia in Non-Hodgkin Lymphoma and Associated Outcomes: A Retrospective Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e123-e129.	0.2	21
34	Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas. <i>American Journal of Hematology</i> , 2018, 93, E1-E3.	2.0	15
35	Extracellular vesicles in leukemia. <i>Leukemia Research</i> , 2018, 64, 52-60.	0.4	38
36	The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody&ndash;drug conjugate for the treatment of newly diagnosed acute myeloid leukemia. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8265-8272.	1.0	27

#	ARTICLE	IF	CITATIONS
37	Bone marrow-specific loss of ABL1 induces myeloproliferative neoplasm with features resembling human myelofibrosis. <i>Blood</i> , 2018, 132, 2053-2066.	0.6	20
38	The next generation of therapy for multiple myeloma: a review of ongoing clinical trials utilizing ClinicalTrials.gov. <i>Future Oncology</i> , 2018, 14, 1965-1976.	1.1	4
39	Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08). <i>Blood</i> , 2018, 132, 2964-2964.	0.6	4
40	Pruritic Rash in a Patient with Hodgkin's Lymphoma. <i>Cureus</i> , 2018, 10, e2450.	0.2	2
41	Diagnosis-to-Treatment Interval As a Prognostic Factor in Aggressive T-Cell Lymphomas. <i>Blood</i> , 2018, 132, 2913-2913.	0.6	0
42	Outcomes Associated with Antimicrobial Use during High Dose Cytarabine Consolidation in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1402-1402.	0.6	0
43	Rhomboid glossitis in disseminated CMV infection. <i>IDCases</i> , 2017, 8, 42-44.	0.4	1
44	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017, 92, 746-751.	2.0	45
45	Hodgkin lymphoma mimicking lung abscess. <i>Blood</i> , 2016, 128, 3011-3011.	0.6	4
46	Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program. <i>Journal of Oncology Practice</i> , 2016, 12, e396-e404.	2.5	12
47	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. <i>Blood</i> , 2016, 128, 3276-3276.	0.6	0
48	Survival of Patients with Del(5q) Syndrome in the Lenalidomide Era. <i>Blood</i> , 2016, 128, 1994-1994.	0.6	0
49	Bortezomib in combination with infusional dose-adjusted <sc>EPOCH</sc> for the treatment of plasmablastic lymphoma. <i>British Journal of Haematology</i> , 2015, 169, 352-355.	1.2	71
50	Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study. <i>Leukemia Research</i> , 2015, 39, 812-817.	0.4	3
51	The Role of Day 14 Bone Marrow Analysis in Determining Leukemia Free Survival and Overall Survival. <i>Blood</i> , 2015, 126, 4974-4974.	0.6	3
52	Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia. <i>Future Oncology</i> , 2014, 10, 1147-1155.	1.1	9
53	Obesity Is Associated With Increased Relative Risk of Diffuse Large B-Cell Lymphoma: A Meta-Analysis of Observational Studies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 122-130.	0.2	36
54	Differences in the clinical course of heparin induced thrombocytopenia before and after the availability of HIT IgG class testing. <i>Thrombosis Research</i> , 2014, 134, 90-92.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Recovery Blasts in the Peripheral Blood in AML Patients Who Obtain a Complete Remission Is a Favorable Prognostic Indicator. <i>Blood</i> , 2014, 124, 5335-5335.	0.6	0
56	Cellular immunotherapy for refractory hematological malignancies. <i>Journal of Translational Medicine</i> , 2013, 11, 150.	1.8	28
57	Cellular Immunotherapy: Using Alloreactivity to Induce Anti-Leukemic Responses without Prolonged Persistence of Donor Cells. <i>Medical Sciences (Basel, Switzerland)</i> , 2013, 1, 37-48.	1.3	0
58	Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage. <i>Blood</i> , 2013, 122, 2459-2459.	0.6	3
59	Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies. <i>Advances in Hematology</i> , 2012, 2012, 1-6.	0.6	5
60	Why is My Patient Neutropenic?. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 253-266.	0.9	6
61	Higher Body Mass Index Is Associated with an Increased Risk of Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 1605-1605.	0.6	0
62	Plasma Cell Myeloma Causing Hyperammonemia Associated with High Inpatient Mortality. <i>Blood</i> , 2012, 120, 5002-5002.	0.6	8
63	Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 151-160.	1.1	14
64	Association Between Obesity/Overweight and Leukemia: A Meta-Analysis of Prospective Cohort Studies. <i>Blood</i> , 2011, 118, 3588-3588.	0.6	4
65	Phase I Trial Examining Addition of Gemcitabine to CHOP in Intermediate Grade NHL. <i>Blood</i> , 2009, 114, 4765-4765.	0.6	0
66	Heparin Induced Thrombocytopenia; A Diagnostic Dilemma. <i>Blood</i> , 2009, 114, 4468-4468.	0.6	0